Vaxxinity (VAXX) Competitors $0.0001 0.00 (0.00%) As of 08/1/2025 03:29 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock VAXX vs. ARTL, BMRA, DWTX, CLRB, SNPX, TAOX, ADXN, TRAW, CYCN, and KPRXShould you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include Artelo Biosciences (ARTL), Biomerica (BMRA), Dogwood Therapeutics (DWTX), Cellectar Biosciences (CLRB), Synaptogenix (SNPX), Synaptogenix (TAOX), Addex Therapeutics (ADXN), Traws Pharma (TRAW), Cyclerion Therapeutics (CYCN), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "pharmaceutical products" industry. Vaxxinity vs. Its Competitors Artelo Biosciences Biomerica Dogwood Therapeutics Cellectar Biosciences Synaptogenix Synaptogenix Addex Therapeutics Traws Pharma Cyclerion Therapeutics Kiora Pharmaceuticals Vaxxinity (NASDAQ:VAXX) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations. Does the media favor VAXX or ARTL? In the previous week, Artelo Biosciences had 3 more articles in the media than Vaxxinity. MarketBeat recorded 3 mentions for Artelo Biosciences and 0 mentions for Vaxxinity. Vaxxinity's average media sentiment score of 0.00 beat Artelo Biosciences' score of -0.02 indicating that Vaxxinity is being referred to more favorably in the media. Company Overall Sentiment Vaxxinity Neutral Artelo Biosciences Neutral Which has higher valuation and earnings, VAXX or ARTL? Artelo Biosciences is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxxinityN/AN/A-$56.93M-$0.450.00Artelo BiosciencesN/AN/A-$9.83M-$17.94-0.57 Do insiders & institutionals have more ownership in VAXX or ARTL? 82.9% of Vaxxinity shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 64.1% of Vaxxinity shares are held by company insiders. Comparatively, 0.8% of Artelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate VAXX or ARTL? Artelo Biosciences has a consensus target price of $25.00, suggesting a potential upside of 145.10%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Artelo Biosciences is more favorable than Vaxxinity.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxxinity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Artelo Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 3 Strong Buy rating(s) 3.60 Which has more risk and volatility, VAXX or ARTL? Vaxxinity has a beta of -23.96, suggesting that its stock price is 2,496% less volatile than the S&P 500. Comparatively, Artelo Biosciences has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Is VAXX or ARTL more profitable? Vaxxinity's return on equity of 0.00% beat Artelo Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets VaxxinityN/A N/A N/A Artelo Biosciences N/A -226.99%-164.61% SummaryVaxxinity and Artelo Biosciences tied by winning 7 of the 14 factors compared between the two stocks. Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VAXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VAXX vs. The Competition Export to ExcelMetricVaxxinityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13K$784.84M$5.52B$9.37BDividend YieldN/A4.84%4.74%4.12%P/E Ratio0.001.3728.8823.80Price / SalesN/A25.69440.8796.33Price / CashN/A19.5635.0756.59Price / Book0.006.688.255.54Net Income-$56.93M-$3.67M$3.25B$259.97M7 Day PerformanceN/A-5.73%-3.75%-4.67%1 Month PerformanceN/A-1.33%2.99%3.28%1 Year PerformanceN/A15.62%25.35%17.92% Vaxxinity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VAXXVaxxinityN/A$0.00flatN/A-99.8%$13KN/A0.0090ARTLArtelo Biosciences2.2361 of 5 stars$12.27-11.9%$25.00+103.7%+26.9%$9.81MN/A-0.685Positive NewsShort Interest ↑Gap DownBMRABiomerica0.1999 of 5 stars$3.44-8.5%N/A+42.9%$9.57M$5.41M-1.4860Positive NewsDWTXDogwood Therapeutics1.4434 of 5 stars$4.80-0.4%$10.00+108.3%N/A$9.21MN/A-0.275Positive NewsUpcoming EarningsCLRBCellectar Biosciences2.6324 of 5 stars$4.71-6.4%$375.00+7,861.8%-92.1%$9.11MN/A-0.2110Positive NewsSNPXSynaptogenixN/A$6.52-22.5%N/A+58.9%$9.06MN/A-0.654TAOXSynaptogenixN/A$6.86+5.2%N/AN/A$9.06MN/A-0.684ADXNAddex Therapeutics2.8762 of 5 stars$8.14-4.8%$30.00+268.6%+2.6%$9.06M$460K-23.9430Positive NewsGap UpTRAWTraws PharmaN/A$1.56-3.7%N/AN/A$9.01M$230K-0.0517Positive NewsCYCNCyclerion TherapeuticsN/A$2.73-1.8%N/A-33.7%$8.92M$2M-2.3530Upcoming EarningsKPRXKiora Pharmaceuticals3.1066 of 5 stars$2.74-6.5%$10.00+265.0%-42.4%$8.92MN/A-0.9410Positive NewsUpcoming Earnings Related Companies and Tools Related Companies Artelo Biosciences Competitors Biomerica Competitors Dogwood Therapeutics Competitors Cellectar Biosciences Competitors Synaptogenix Competitors Synaptogenix Competitors Addex Therapeutics Competitors Traws Pharma Competitors Cyclerion Therapeutics Competitors Kiora Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VAXX) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
